Alterity Therapeutics Management
Management criteria checks 3/4
Alterity Therapeutics' CEO is David Stamler, appointed in Jan 2021, has a tenure of 3.83 years. total yearly compensation is A$1.42M, comprised of 50.4% salary and 49.6% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth €19.53K. The average tenure of the management team and the board of directors is 11.4 years and 18.5 years respectively.
Key information
David Stamler
Chief executive officer
AU$1.4m
Total compensation
CEO salary percentage | 50.4% |
CEO tenure | 3.8yrs |
CEO ownership | 0.2% |
Management average tenure | 11.4yrs |
Board average tenure | 18.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | AU$1m | AU$717k | -AU$19m |
Mar 31 2024 | n/a | n/a | -AU$16m |
Dec 31 2023 | n/a | n/a | -AU$12m |
Sep 30 2023 | n/a | n/a | -AU$13m |
Jun 30 2023 | AU$2m | AU$731k | -AU$14m |
Mar 31 2023 | n/a | n/a | -AU$14m |
Dec 31 2022 | n/a | n/a | -AU$14m |
Sep 30 2022 | n/a | n/a | -AU$14m |
Jun 30 2022 | AU$2m | AU$658k | -AU$13m |
Mar 31 2022 | n/a | n/a | -AU$13m |
Dec 31 2021 | n/a | n/a | -AU$13m |
Sep 30 2021 | n/a | n/a | -AU$14m |
Jun 30 2021 | AU$979k | AU$606k | -AU$15m |
Mar 31 2021 | n/a | n/a | -AU$16m |
Dec 31 2020 | n/a | n/a | -AU$16m |
Sep 30 2020 | n/a | n/a | -AU$15m |
Jun 30 2020 | AU$625k | AU$625k | -AU$13m |
Mar 31 2020 | n/a | n/a | -AU$13m |
Dec 31 2019 | n/a | n/a | -AU$13m |
Sep 30 2019 | n/a | n/a | -AU$12m |
Jun 30 2019 | AU$548k | AU$548k | -AU$12m |
Mar 31 2019 | n/a | n/a | -AU$11m |
Dec 31 2018 | n/a | n/a | -AU$10m |
Sep 30 2018 | n/a | n/a | -AU$9m |
Jun 30 2018 | AU$630k | AU$504k | -AU$8m |
Compensation vs Market: David's total compensation ($USD931.10K) is above average for companies of similar size in the German market ($USD492.37K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Stamler (63 yo)
3.8yrs
Tenure
AU$1,422,068
Compensation
Dr. David A. Stamler, M.D., serves as Chief Executive Officer at Alterity Therapeutics Limited since January 07, 2021. Dr. Stamler had been the Chief Medical Officer and Senior Vice President of Clinical D...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder & Non-Executive Chairman | 27yrs | AU$280.00k | 0.28% € 27.0k | |
Chief Executive Officer | 3.8yrs | AU$1.42m | 0.20% € 19.5k | |
Chief Financial Officer | less than a year | no data | no data | |
Chief Scientific Advisor and Member of Research & Development Advisory Board | 12.8yrs | no data | no data | |
Chief Medical Advisor | 17.7yrs | no data | no data | |
Head of Research | 17.6yrs | no data | no data | |
Company Secretary | 10yrs | no data | no data |
11.4yrs
Average Tenure
65.5yo
Average Age
Experienced Management: PBN0's management team is seasoned and experienced (11.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder & Non-Executive Chairman | 27yrs | AU$280.00k | 0.28% € 27.0k | |
Chief Scientific Advisor and Member of Research & Development Advisory Board | 17.7yrs | no data | no data | |
Non-Executive Independent Director | 24.9yrs | AU$70.00k | 0.14% € 13.6k | |
Member of Research & Development Advisory Board | 17.7yrs | AU$241.36k | no data | |
Non-Executive Independent Director | 19.3yrs | AU$70.00k | 0.14% € 13.1k | |
Non-Executive Director | 13.3yrs | AU$70.00k | no data | |
Chairman of Research & Development Advisory Board | no data | AU$78.76k | no data |
18.5yrs
Average Tenure
69yo
Average Age
Experienced Board: PBN0's board of directors are seasoned and experienced ( 18.5 years average tenure).